Arcus Biosciences, Inc.
NYSE:RCUSBiotechnology
-$0.09 today
- Market cap
- $2.27B
- Beta
- 0.84
- P/E (TTM)
- -8.2
- EPS (TTM)
- -$2.94
Volume 1.97M
Average 1.17M
RCUS Net Receivables
Amounts owed to the company by customers and others, net of allowances for uncollectible accounts.
Arcus Biosciences, Inc.NYSE: RCUS
Net Receivables · Q2 FY2026 · quarter ended Jun 2026
Net receivables rises 80.0% from a year ago
Net receivables stood at $36M at the end of Q2 FY2026, up 80.0% from a year earlier and up 414.3% from the prior quarter. Over 3 fiscal years it compounded at -28.1% a year.
Context
- Net receivables amounted to 3.9% of total assets at the end of Q2 FY2026, up 2.0 pp from a year earlier.
- Net receivables increased in 0 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether net receivables keeps rising in the next quarterly balance sheet after a +80.0% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Net Receivables history
USD · from the balance sheet
- Latest · FY2025
- 16M USD
- Year-over-year change
- -36.0%
- 4-year CAGR
- -61.7%
| Period | Period end | Net Receivables | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 16M | -36.0% |
| FY2024 | 2024-12-31 | 25M | -40.5% |
| FY2023 | 2023-12-31 | 42M | -2.3% |
| FY2022 | 2022-12-31 | 43M | -94.2% |
| FY2021 | 2021-12-31 | 746.82M | — |
Net Receivables vs competitors
How RCUS compares with its peers on the latest reported figures
- RCUS's Jun 2026 net receivables of $36M is the 4th highest of the 9 companies compared; the peer median is $20.24M.
- Its year-over-year change of +80.0% is the 3rd highest of 5, against a peer median of +220.7%.
- Net receivables amounts to 3.9% of total assets for RCUS, versus a peer median of 2.3%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Jun 2026 | $108.58M | +989.3% | +120.9% | 20.8% | |
| Jun 2026 | $75M | — | — | 6.8% | |
| Sep 2026 | $53.6M | +59.0% | +182.5% | 8.8% | |
| Jun 2026 | $36M | +80.0% | -28.1% | 3.9% | |
| Mar 2026 | $24.35M | -3.5% | +12.9% | 3.3% | |
| Mar 2026 | $16.13M | +382.4% | +68.6% | 1.4% | |
| Jun 2026 | $3.93M | — | -38.3% | 0.3% | |
| Jun 2026 | $0 | — | — | 0.0% | |
| Jun 2026 | $0 | — | — | 0.0% | |
| Peer median (excluding RCUS) | $20.24M | +220.7% | +68.6% | 2.3% | |
Competitors are the stored peer set for RCUS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 147.91M | 206M | 127M | 150M | 222M |
| Short-term Investments | 351.39M | 803M | 632M | 828M | 759M |
| Net Receivables | 746.82M | 43M | 42M | 25M | 16M |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Other Current Assets | 14.72M | 14M | 30M | 13M | 10M |
| Total Current Assets | 1.26B | 1.07B | 831M | 1.02B | 1.01B |
| Property, Plant & Equipment (Net) | 137.42M | 135M | 51M | 47M | 40M |
| Goodwill | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 |
| Long-term Investments | 185M | 134M | 107M | 14M | 29M |
| Tax Assets | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Assets | 7.73M | 10M | 106M | 73M | 63M |
| Total Non-current Assets | 330.15M | 279M | 264M | 134M | 132M |
| Total Assets | 1.59B | 1.35B | 1.1B | 1.15B | 1.14B |
| Account Payables | 10.26M | 20M | 17M | 18M | 42M |
| Short-term Debt | 5.1M | 3M | 0 | 0 | 0 |
| Tax Payables | 1.82M | 0 | 0 | 1M | 0 |
| Deferred Revenue | 102M | 97M | 91M | 85M | 35M |
| Other Current Liabilities | 30.26M | 48M | 39M | 14M | 18M |
| Total Current Liabilities | 166.08M | 193M | 184M | 226M | 231M |
| Long-term Debt | 0 | 0 | 0 | 48M | 99M |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue (Non-current) | 462.22M | 355M | 307M | 234M | 43M |
| Other Non-current Liabilities | 5.26M | 23M | 142M | 157M | 135M |
| Total Non-current Liabilities | 584.36M | 495M | 449M | 439M | 277M |
| Total Liabilities | 750.45M | 688M | 633M | 665M | 508M |
| Common Stock | 7K | 1.21B | 1.31B | 1.62B | 2.12B |
| Retained Earnings | (275.35M) | (542M) | (849M) | (1.13B) | (1.49B) |
| Accumulated OCI | (1.26M) | (7M) | 0 | 0 | 0 |
| Other Stockholders Equity | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
| Total Equity | 841.45M | 657M | 462M | 485M | 631M |
| Total Debt | 121.99M | 120M | 11M | 60M | 112M |
| Net Debt | (25.93M) | (86M) | (116M) | (90M) | (110M) |
Arcus Biosciences, Inc.
NYSE:RCUS
Intrinsic Alpha fair value
Locked
Current Price
$15.76
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.